Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Nov:464:83-7.
doi: 10.1097/BLO.0b013e31812f79a9.

Knee arthroplasty in the young patient: survival in a community registry

Affiliations
Multicenter Study

Knee arthroplasty in the young patient: survival in a community registry

Terence J Gioe et al. Clin Orthop Relat Res. 2007 Nov.

Abstract

Operative options for the younger patient with an arthritic knee remain controversial. We prospectively followed 1047 patients 55 years old or younger who underwent knee arthroplasty in a community joint registry over a 14-year period. Patients were implanted with 1047 joints of three predominant designs by 48 surgeons in four hospitals associated with a community joint registry. The mean age for this cohort was 49.8 years, and 62.8% (657/1047) of the patients were female. There were a total of 73 revisions performed, 5.6% (37/653) in women and 9.2% (36/394) in men. Cemented TKAs performed best, with a cumulative revision rate of 15.5%, compared to 32.3% in unicompartmental knee arthroplasty (UKA) patients and 34.1% in cementless designs. Men had a higher cumulative revision rate than women, 31.9% compared to 20.6%. Adjusting for implant type and gender, there was no difference in cumulative revision rate based on diagnosis (OA versus other) or age group (< or = 40, 41-45, 46-50, 51-55 years) or between cruciate-retaining and -substituting designs. Eighty five percent of cemented TKA implants survived at 14 years in the population under 55 years of age in this community registry. Cementless designs and UKA increased revision risk independently.

Level of evidence: Level II, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

PubMed Disclaimer

Similar articles

Cited by

Publication types